Foldax, Inc. Gains Approval to Begin US Clinical Trials of the First and Only Biopolymer Heart Valve Platform

Disclosure: This site contains some affiliate links. We might receive a small commission at no additional cost to you.

Written & Supervised By
Preventive Medicine and Public Health Specialist | 40+ Years Experience

Medically Reviewed
Dr. Jose Rossello, MD, PhD, MHCM
Preventive Medicine & Public Health Specialist
Last Reviewed: February 21, 2019

SALT LAKE CITY–( BUSINESS WIRE )–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease.

Read the source article at businesswire.com[1]

author avatar
Jose Rossello, MD, PhD, MHCM
Dr. Rossello is a medical doctor specializing in Preventive Medicine and Public Health. He founded PreventiveMedicineDaily.com to provide evidence-based health information supported by authoritative medical research.
See Full Bio
Previous
Next
Leave a Comment

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}